Last 12 months
Inside the activity.
0 purchase rows · 27 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 7 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 10 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 23, 2018 Filed Apr 24, 2018 23:41 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 2,915 | $51.00 | $148,665.00 |
DisclosureSEC source: 0000899243-18-010682 · doc4.xml · nonDerivative · entry 8 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 50,072 F14 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $54.00 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F15 · ownership.nature: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 23, 2018 Filed Apr 24, 2018 23:41 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 2,630 | $51.00 | $134,130.00 |
DisclosureSEC source: 0000899243-18-010682 · doc4.xml · nonDerivative · entry 7 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 45,171 F12 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. ("VAF V"). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $54.00 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F13 · ownership.nature: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 23, 2018 Filed Apr 24, 2018 23:41 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 89,628 | $50.66 | $4,540,554.48 |
DisclosureSEC source: 0000899243-18-010682 · doc4.xml · nonDerivative · entry 6 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,539,576 F9 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ventures Capital V, L.P. ("VVC V"). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $54.00 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F11 · ownership.nature: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 23:44 UTC |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Ventures IV, LLC10% owner
Versant Venture Capital V, L.P.10% owner
Versant Affiliates Fund V, L.P.10% owner
|
OtherCommon Shares | 92,918 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010684 · doc4.xml · nonDerivative · entry 4 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Ventures IV, LLC · CIK 0001456589 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F7 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV IV without consideration to its members. F6 · ownership.nature: The shares are held by VV IV. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 23:44 UTC |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Ventures IV, LLC10% owner
Versant Venture Capital V, L.P.10% owner
Versant Affiliates Fund V, L.P.10% owner
|
OtherCommon Shares | 92,918 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010684 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Ventures IV, LLC · CIK 0001456589 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 92,918 F5 · kind: Represents a change in the form of ownership of VV IV by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC IV and VSF IV. F6 · ownership.nature: The shares are held by VV IV. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 23:44 UTC |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Ventures IV, LLC10% owner
Versant Venture Capital V, L.P.10% owner
Versant Affiliates Fund V, L.P.10% owner
|
OtherCommon Shares | 2,947 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010684 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Ventures IV, LLC · CIK 0001456589 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 13,277 F3 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("VSF IV") without consideration to its partners. F4 · ownership.nature: These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interest therein. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 23:44 UTC |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Ventures IV, LLC10% owner
Versant Venture Capital V, L.P.10% owner
Versant Affiliates Fund V, L.P.10% owner
|
OtherCommon Shares | 497,053 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010684 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Ventures IV, LLC · CIK 0001456589 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,238,979 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("VVC IV") without consideration to its partners. F2 · ownership.nature: These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interest therein. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 23:42 UTC |
Woiwode ThomasDirector
|
OtherCommon Shares | 2,323 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010683 · doc4.xml · nonDerivative · entry 5 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,282 F8 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VV IV to its members. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 23:42 UTC |
Woiwode ThomasDirector
|
OtherCommon Shares | 92,918 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010683 · doc4.xml · nonDerivative · entry 4 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F7 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV IV without consideration to its members. F6 · ownership.nature: The shares are held by VV IV. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 23:42 UTC |
Woiwode ThomasDirector
|
OtherCommon Shares | 92,918 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010683 · doc4.xml · nonDerivative · entry 3 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 92,918 F5 · kind: Represents a change in the form of ownership of VV IV by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC IV and VSF IV. F6 · ownership.nature: The shares are held by VV IV. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 23:42 UTC |
Woiwode ThomasDirector
|
OtherCommon Shares | 2,947 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010683 · doc4.xml · nonDerivative · entry 2 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 13,277 F3 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("VSF IV") without consideration to its partners. F4 · ownership.nature: These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 23:42 UTC |
Woiwode ThomasDirector
|
OtherCommon Shares | 497,053 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010683 · doc4.xml · nonDerivative · entry 1 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,238,979 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("VVC IV") without consideration to its partners. F2 · ownership.nature: These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 23:41 UTC |
Bolzon Bradley J PhDDirector
|
OtherCommon Shares | 16,262 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010682 · doc4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,986 F8 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VV IV to its members. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 23:41 UTC |
Bolzon Bradley J PhDDirector
|
OtherCommon Shares | 92,918 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010682 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F7 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV IV without consideration to its members. F6 · ownership.nature: The shares are held by VV IV. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 23:41 UTC |
Bolzon Bradley J PhDDirector
|
OtherCommon Shares | 92,918 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010682 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 92,918 F5 · kind: Represents a change in the form of ownership of VV IV by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC IV and VSF IV. F6 · ownership.nature: The shares are held by VV IV. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 23:41 UTC |
Bolzon Bradley J PhDDirector
|
OtherCommon Shares | 2,947 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010682 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 13,277 F3 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("VSF IV") without consideration to its partners. F4 · ownership.nature: These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 23:41 UTC |
Bolzon Bradley J PhDDirector
|
OtherCommon Shares | 497,053 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010682 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,238,979 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("VVC IV") without consideration to its partners. F2 · ownership.nature: These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 20:50 UTC |
Kulkarni SamarthChief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $19.12 | $0.00 |
DisclosureSEC source: 0000899243-18-010320 · doc4.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Shares · 75,000 shares Expires 2027-12-01 F1 · derivative.exercise_date: This performance-based option was granted on December 1, 2017 with respect to 75,000 Common Shares, with 75% of the shares vesting on December 1, 2020 and the remaining 25% of the shares vesting on December 1, 2021. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 21:54 UTC |
Ho Tony WSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 53,000 | $0.00 Strike: $51.49 | $0.00 |
DisclosureSEC source: 0000899243-18-006957 · doc4.xml · derivative · entry 1 Ho Tony W · CIK 0001713637 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Shares · 53,000 shares Expires 2028-03-07 F1 · derivative.exercise_date: This option was granted on March 7, 2018 and shall vest in 48 equal monthly installments. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 21:50 UTC |
Kulkarni SamarthChief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 136,000 | $0.00 Strike: $51.49 | $0.00 |
DisclosureSEC source: 0000899243-18-006956 · doc4.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,000 Underlying: Common Shares · 136,000 shares Expires 2028-03-07 F1 · derivative.exercise_date: This option was granted on March 7, 2018 and shall vest in 48 equal monthly installments. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 21:50 UTC |
KASINGER JAMES R.General Counsel and Secretary
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $51.49 | $0.00 |
DisclosureSEC source: 0000899243-18-006955 · doc4.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2028-03-07 F1 · derivative.exercise_date: This option was granted on March 7, 2018 and shall vest in 48 equal monthly installments. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 21:50 UTC |
TOMSICEK MICHAEL JOHNChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $51.49 | $0.00 |
DisclosureSEC source: 0000899243-18-006954 · doc4.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2028-03-07 F1 · derivative.exercise_date: This option was granted on March 7, 2018 and shall vest in 48 equal monthly installments. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:38 UTC |
Dylan-Hyde TylerChief Legal Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 19,890 | $0.00 Strike: $12.57 | $0.00 |
DisclosureSEC source: 0000899243-18-001348 · doc4.xml · derivative · entry 7 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,237 Underlying: Common Shares · 19,890 shares Expires 2026-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This performance-based option was granted on July 15, 2016 with respect to 26,667 Common Shares with 100% of the shares vesting within 12 months of the date of grant, subject to the satisfaction of mutually agreed upon performance metrics. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:38 UTC |
Dylan-Hyde TylerChief Legal Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,110 | $0.00 Strike: $12.57 | $0.00 |
DisclosureSEC source: 0000899243-18-001348 · doc4.xml · derivative · entry 6 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,663 Underlying: Common Shares · 1,110 shares Expires 2026-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on July 15, 2016 with respect to 53,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:38 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 19,890 | $28.10 | $558,909.00 |
DisclosureSEC source: 0000899243-18-001348 · doc4.xml · nonDerivative · entry 5 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.85 to $28.75, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:38 UTC |
Dylan-Hyde TylerChief Legal Officer
|
Exercise / conversionCommon Shares | 19,890 | $12.57 | $250,017.30 |
DisclosureSEC source: 0000899243-18-001348 · doc4.xml · nonDerivative · entry 4 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:38 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 1,110 | $28.24 | $31,346.40 |
DisclosureSEC source: 0000899243-18-001348 · doc4.xml · nonDerivative · entry 3 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:38 UTC |
Dylan-Hyde TylerChief Legal Officer
|
Exercise / conversionCommon Shares | 1,110 | $12.57 | $13,952.70 |
DisclosureSEC source: 0000899243-18-001348 · doc4.xml · nonDerivative · entry 2 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:38 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 45,000 | $28.00 | $1,260,000.00 |
DisclosureSEC source: 0000899243-18-001348 · doc4.xml · nonDerivative · entry 1 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $28.75, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 21:39 UTC |
EMSTER KURT VONDirector
|
SaleCommon Shares | 92,337 | $26.96 | $2,489,405.52 |
DisclosureSEC source: 0000905718-18-000047 · crisprfm4_jan52018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,821,268 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("Abingworth") on May 15, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.50 to $28.35 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: These shares are held by Abingworth. Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| January 05, 2018 Filed Jan 12, 2018 02:00 UTC |
EMSTER KURT VONDirector
|
PurchaseCommon Shares | 65,934 | $22.75 | $1,499,998.50 |
DisclosureSEC source: 0000905718-18-000054 · crisprabefm4_jan52018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,887,202 F1 · ownership.nature: Shares are held by Abingworth Bioequities Master Fund Limited ("ABE"). Abingworth LLP is the investment manager of ABE and has been delegated with all investment and dispositive power over the securities held by ABE. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABE. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABE to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 05, 2018 Filed Jan 30, 2018 14:21 UTC |
BAYER AKTIENGESELLSCHAFT10% owner
Bayer Global Investments B.V.10% owner
|
PurchaseCommon Shares | 527,472 | $22.75 | $11,999,988.00 |
DisclosureSEC source: 0000029905-18-000006 · edgar.xml · nonDerivative · entry 1 BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Bayer Global Investments B.V. · CIK 0001685417 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By subsidiary Disclosed balance after: 5,632,802 F1 · ownership.nature: Represents purchase by Bayer Global Investments B.V. ("Bayer BV"). Bayer BV is the Direct Owner of 5,632,802 common shares of CRISPR Therapeutics AG ("CRISR"). This Form 4 is a joint filing of Bayer BV and Bayer AG. Bayer AG is the 100% Indirect Owner through subsidiaries of the same shares as to which Bayer BV is the Direct Owner. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:29 UTC |
EMSTER KURT VONDirector
|
SaleCommon Shares | 37,754 | $26.76 | $1,010,123.37 |
DisclosureSEC source: 0000905718-18-000020 · crisprfm4_jan22018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,913,605 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("Abingworth") on May 15, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.50 to $27.36 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: These shares are held by Abingworth. Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 00:14 UTC |
Dylan-Hyde TylerChief Legal Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,510 | $0.00 Strike: $12.57 | $0.00 |
DisclosureSEC source: 0000899243-18-000520 · doc4.xml · derivative · entry 5 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,157 Underlying: Common Shares · 1,510 shares Expires 2026-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This performance-based option was granted on July 15, 2016 with respect to 26,667 Common Shares with 100% of the shares vesting within 12 months of the date of grant, subject to the satisfaction of mutually agreed upon performance metrics. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 00:14 UTC |
Dylan-Hyde TylerChief Legal Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,490 | $0.00 Strike: $12.57 | $0.00 |
DisclosureSEC source: 0000899243-18-000520 · doc4.xml · derivative · entry 4 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,773 Underlying: Common Shares · 6,490 shares Expires 2026-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 15, 2016 with respect to 53,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 00:14 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 8,000 | $25.75 | $206,000.00 |
DisclosureSEC source: 0000899243-18-000520 · doc4.xml · nonDerivative · entry 3 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 00:14 UTC |
Dylan-Hyde TylerChief Legal Officer
|
Exercise / conversionCommon Shares | 8,000 | $12.57 | $100,560.00 |
DisclosureSEC source: 0000899243-18-000520 · doc4.xml · nonDerivative · entry 2 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 00:14 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 30,000 | $20.55 | $616,500.00 |
DisclosureSEC source: 0000899243-18-000520 · doc4.xml · nonDerivative · entry 1 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.5788 to $25.71, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 21:18 UTC |
Dylan-Hyde TylerChief Legal Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 9,070 | $0.00 Strike: $12.57 | $0.00 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · derivative · entry 11 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,263 Underlying: Common Shares · 9,070 shares Expires 2026-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on July 15, 2016 with respect to 53,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 21:18 UTC |
Dylan-Hyde TylerChief Legal Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,230 | $0.00 Strike: $14.43 | $0.00 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · derivative · entry 10 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,070 Underlying: Common Shares · 6,230 shares Expires 2027-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on June 15, 2017 with respect to 65,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on July 15, 2017. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 21:18 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 15,000 | $22.68 | $340,200.00 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · nonDerivative · entry 8 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.6771 to $23.00, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 21:18 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 8,000 | $23.76 | $190,080.00 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · nonDerivative · entry 7 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.7606 to $23.90, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 21:18 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 1,070 | $21.75 | $23,272.50 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · nonDerivative · entry 6 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 21:18 UTC |
Dylan-Hyde TylerChief Legal Officer
|
Exercise / conversionCommon Shares | 9,070 | $12.57 | $114,009.90 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · nonDerivative · entry 5 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 21:18 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 6,230 | $21.75 | $135,502.50 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · nonDerivative · entry 4 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 21:18 UTC |
Dylan-Hyde TylerChief Legal Officer
|
Exercise / conversionCommon Shares | 6,230 | $14.43 | $89,898.90 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · nonDerivative · entry 3 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 21:18 UTC |
Dylan-Hyde TylerChief Legal Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 700 | $0.00 Strike: $14.43 | $0.00 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · derivative · entry 9 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,300 Underlying: Common Shares · 700 shares Expires 2027-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on June 15, 2017 with respect to 65,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on July 15, 2017. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 21:18 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 700 | $21.75 | $15,225.00 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · nonDerivative · entry 2 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 21:18 UTC |
Dylan-Hyde TylerChief Legal Officer
|
Exercise / conversionCommon Shares | 700 | $14.43 | $10,101.00 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · nonDerivative · entry 1 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2017 Filed Dec 27, 2017 21:17 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 15,000 | $20.55 | $308,250.00 |
DisclosureSEC source: 0000899243-17-029619 · doc4.xml · nonDerivative · entry 1 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.5504 to $20.56, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.